San Antonio, United States
Hera Biotech, founded in 2020, is innovating in the field of Women's Health Diagnostics with a focus on addressing the needs in biopharma, biotechnology, healthcare, and pharmaceuticals. The company's mission is encapsulated in its slogan, "Advancing the Standard of Care in Women's Health Diagnostics."
Operating from its headquarters in the United States, Hera Biotech is pioneering the development of a scalable diagnostic platform aimed at two crucial yet underdiagnosed conditions—endometriosis and cervical cancer. These conditions represent significant unmet needs in women's health globally, providing potential for impactful advances in patient care.
The company recently secured a $15.00M Series A investment as of 01 January 2024, enabling further expansion and advancement of their diagnostic innovations. This investment reflects confidence in their ability to revolutionize diagnostics in these critical health areas, progressively setting a new standard in the industry.
